Oramed Announces Last Patient Treated in Pivotal Phase IIb Trial of Oral Insulin ORMD-0801

Topline data readout expected Q4 2019 NEW YORK, Sept. 17, 2019 /PRNewswire/ —  Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced the treatment of the last patient in the primary cohort of the Phase IIb HbA1c trial evaluating Oramed’s lead oral insulin […]